PR
KNSA icon

PSP Research’s Kiniksa Pharmaceuticals KNSA Stock Holding History

PSP Research’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Sell
5,000
-4,000
-44% -$207K 0.17% 45
2026
Q1 		$433K Sell
9,000
-3,655
-29% -$162K 0.31% 42
2025
Q4 		$522K Buy
+12,655
New +$508K 0.46% 63

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

PSP Research's KNSA Position: Q2 2026 in Review

PSP Research reduced its Kiniksa Pharmaceuticals (KNSA) stake by 44% in Q2 2026, selling an estimated $207K and leaving 5,000 shares worth $320K. The position accounts for 0.17% of the portfolio, ranked #45.

PSP Research first reported a position in KNSA in Q4 2025 and has held it in 3 quarters since. The position peaked at $522K in Q4 2025. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • PSP Research held 5,000 shares of Kiniksa Pharmaceuticals worth $320K as of Q2 2026.
  • PSP Research sold 4,000 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Kiniksa Pharmaceuticals made up 0.17% of PSP Research's portfolio in Q2 2026, its #45 holding.
  • PSP Research first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Kiniksa Pharmaceuticals position peaked at $522K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.